A bionic aggregation-induced emission (AIE) photosensitizer system (THL) was developed to enhance cancer immunotherapy by combining cold exposure therapy (CE) with photodynamic therapy (PDT). THL, designed to mimic tumor-derived exosomes, targets tumor cells efficiently and generates reactive oxygen species (ROS) under light irradiation. CE therapy reduces glucose, ATP, and glutathione (GSH) levels in tumor tissue, enhancing THL-mediated PDT and ROS production. This combination therapy inhibits tumor growth, prevents recurrence, and increases the number of cytotoxic CD8+ T cells and memory T cells. THL also induces immunogenic cell death (ICD) by promoting the release of damage-associated molecular patterns (DAMPs) and maturing dendritic cells (DCs), which enhances immune responses against cancer. In vivo studies showed that THL combined with CE significantly reduced tumor size, improved survival rates, and enhanced immune memory, making it a promising strategy for cancer immunotherapy. The system demonstrates good biosafety and has potential for clinical application. Future research will explore combining CE with other therapies like radiotherapy and chemotherapy to further improve treatment outcomes.A bionic aggregation-induced emission (AIE) photosensitizer system (THL) was developed to enhance cancer immunotherapy by combining cold exposure therapy (CE) with photodynamic therapy (PDT). THL, designed to mimic tumor-derived exosomes, targets tumor cells efficiently and generates reactive oxygen species (ROS) under light irradiation. CE therapy reduces glucose, ATP, and glutathione (GSH) levels in tumor tissue, enhancing THL-mediated PDT and ROS production. This combination therapy inhibits tumor growth, prevents recurrence, and increases the number of cytotoxic CD8+ T cells and memory T cells. THL also induces immunogenic cell death (ICD) by promoting the release of damage-associated molecular patterns (DAMPs) and maturing dendritic cells (DCs), which enhances immune responses against cancer. In vivo studies showed that THL combined with CE significantly reduced tumor size, improved survival rates, and enhanced immune memory, making it a promising strategy for cancer immunotherapy. The system demonstrates good biosafety and has potential for clinical application. Future research will explore combining CE with other therapies like radiotherapy and chemotherapy to further improve treatment outcomes.